Faro AI secures $37M Series B to accelerate clinical trials with artificial intelligence

Faro AI, a San Diego‑based startup, announced a $37 million Series B financing round aimed at expanding its artificial‑intelligence platform.

The new funding will be directed toward developing tools that seek to shorten the lengthy clinical‑trial phase, which often extends for years before a drug reaches patients.

Unlike many AI ventures that concentrate on speeding up molecule design, Faro focuses on the later stages of drug development, targeting trial design, patient recruitment and data analysis to improve efficiency.

Investors view the round as a sign of growing confidence in AI’s ability to reduce trial costs and accelerate market entry for new therapies.